Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Hampp

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Annals of Hematology|September 2, 2025
Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical reviewPau Abrisqueta, Ana Jiménez-Ubieto, Ángel Serna, et al.
Obstetrics and Gynecology|December 25, 2012
Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007Jean M Lawrence, Susan E Andrade, Lyndsay A Avalos, et al.
Blood Cancer Journal|April 1, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United StatesShaji Kumar, Katja C Weisel, Paul Spin, et al.
Leukemia & Lymphoma|February 25, 2026
Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphomaEmmanuel Bachy, James Harnett, Katharina Prochazka, et al.
Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
Drug Safety|August 5, 2025
Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation StrategiesCeleste L Y Ewig, Yanning Wang, Nicole E Smolinski, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Annals of Hematology|September 2, 2025
Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical reviewPau Abrisqueta, Ana Jiménez-Ubieto, Ángel Serna, et al.
Obstetrics and Gynecology|December 25, 2012
Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007Jean M Lawrence, Susan E Andrade, Lyndsay A Avalos, et al.
Blood Cancer Journal|April 1, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United StatesShaji Kumar, Katja C Weisel, Paul Spin, et al.
Leukemia & Lymphoma|February 25, 2026
Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphomaEmmanuel Bachy, James Harnett, Katharina Prochazka, et al.
Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
Drug Safety|August 5, 2025
Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation StrategiesCeleste L Y Ewig, Yanning Wang, Nicole E Smolinski, et al.
Pageof 6